Terms ending in 2034
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,539,218 | Prevention and Treatment of Thromboembolic Disorders In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,087,183 | Forms of Methyl {4,6-Diamino-2-[1 (2-Fluorobenzyl)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL Carbamate In force · Medium confidence | Adverio Pharma GmbH | In force | Medium confidence | |
| US 10,662,188 | Forms of Methyl {4,6-Diamino-2-[1 (2-Fluorobenzyl)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL Carbamate In force · Medium confidence | Adverio Pharma GmbH | In force | Medium confidence | |
| US 11,203,593 | Forms of Methyl {4,6-Diamino-2-[1 (2-Fluorobenzyl)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL Carbamate In force · Medium confidence | Adverio Pharma GmbH | In force | Medium confidence | |
| US 12,503,469 | Forms of Methyl {4,6-Diamino-2-[1 (2-Fluorobenzyl)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL Carbamate In force · Medium confidence | Adverio Pharma GmbH | In force | Medium confidence | |
| US 9,018,258 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof In force · High confidence | Bayer Intellectual Property GmbH | In force | High confidence | |
| US 10,183,932 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 10,226,469 | Use of Substituted 2,3-Dihydroimidazo[1,2-c]quinazolines for Treating Lymphomas In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 9,414,797 | Combination of Contrast Medium and Mammography CT System with a Prespecified Energy Range and Method for Generating Tomographic Mammography CT Images by This Combination In force · High confidence | Siemens Healthineers AG | In force | High confidence | |
| US 11,052,128 | Formulation for Bispecific T-Cell Engagers (BITES) In force · High confidence | Amgen Inc. | In force | High confidence | |
| 9 more term ends in 2034 · Pro | |||||
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19.
13 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.